Market Overview:
The global Gaucher disease market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as increasing prevalence of Gaucher disease, rising awareness about Gaucher disease, and technological advancements in the field of enzyme replacement therapy (ERT) and substrate reduction therapy (SRT). However, high cost associated with ERT and SRT therapies is likely to restrain the growth of this market during the forecast period. The global Gaucher disease market can be segmented on the basis of type into ERT, SRT, and others. The ERT segment is expected to account for a major share of the global Gaucher disease market in 2018. This segment is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The SRT segment is projected to grow at a higher CAGR than that for ERT during the forecast period owing its potential benefits over traditional therapies such as reduced dosage requirements and fewer side effects. On basis application non-neuronopathic gauchers diseases are more common accounting for majority share while neuronopathic gauchers diseases are less common but have serious consequences .Non-neuronopathic gauchers diseases are further sub divided into three types: Type 1 which affects red blood cells; type 2 which affects liver; type 3 which affects spleen .
Product Definition:
Gaucher disease is a rare, inherited disorder that causes the body to produce too little of an enzyme called glucocerebrosidase. This enzyme is responsible for breaking down a certain type of sugar molecule. When the body does not have enough glucocerebrosidase, these sugar molecules can build up and cause damage to various organs and tissues. Gaucher disease can affect people in different ways, depending on the severity of their deficiency in glucocerebrosidase. Symptoms may include enlarged liver and spleen, bone pain and fractures, neurological problems (such as seizures), breathing difficulties, skin lesions, and anemia. The most common form of Gaucher disease occurs when only one gene mutation is present (known as type 1 Gaucher disease). A less common form of the disorder (known as type 2 Gaucher disease) results from two gene mutations. There is currently no cure for Gaucher disease; however treatments are available to help manage symptoms.
Enzyme Replacement Therapy:
Enzyme replacement therapy, ERT, is a treatment for patients with rare and life-threatening diseases of the immune system. The enzyme replacement therapy market is expected to grow at a lucrative rate during the forecast period owing to increasing incidences of Gaucher disease worldwide. According to data published by National Institute of Health in 2019, around 10-20 cases per million are reported annually in U.S., whereas approximately 100 cases per million are reported in Europe and Asia (combined).
Substrate Reduction Therapy:
Substrate reduction therapy.
Gaucher disease (GD) is a rare genetic disorder that affects the body’s ability to produce certain fatty substances, resulting in bone marrow damage and eventually death.
Application Insights:
Non-neuronopathic gaucher disease held the largest share of over 80.0% in 2017. The application of enzyme replacement therapy is one of the major factors contributing to the large share held by this segment. Enzyme replacement therapies are used in Gaucher disease due to its non-neuronopathic form, which has resulted in higher market penetration for this segment.
The neuronopathic Gaucher disease segment is expected to register a significant CAGR during the forecast period owing to increasing awareness about availability of advanced treatment options and growing research initiatives by various companies including Novartis, Pfizer, sanofi pasteur and others for discovering new drugs specific for this condition.
Regional Analysis:
Europe dominated the global market in terms of revenue share in 2017. The presence of a large number of patients suffering from Gaucher disease and high healthcare expenditure are some factors attributing to its largest share. In addition, the availability of reimbursement facilities for enzyme replacement therapies is also expected to boost its growth over the forecast period.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to rising disposable income, increasing awareness about Gaucher disease treatment options, and growing generic drug manufacturing industry in emerging economies such as China & India. Furthermore, increasing medical tourism due to affordable treatments offered by countries such as Japan & South Korea is also anticipated fuel regional market growth during the forecast period (2018-2030).
Growth Factors:
- Increasing incidence of Gaucher Disease
- Growing awareness about Gaucher Disease
- Rising demand for better treatment options for Gaucher Disease patients
- Technological advancements in the field of gene therapy and drug discovery for treating Gaucher Disease
- Availability of government funding and support to research organizations working on developing new treatments for Gaucher Disease
Scope Of The Report
Report Attributes
Report Details
Report Title
Gaucher Disease Market Research Report
By Type
Enzyme Replacement Therapy, Substrate Reduction Therapy,
By Application
Non-neuronopathic Gaucher Disease, Neuronopathic Gaucher Disease,
By Companies
Sanofi, Takeda, Actelion Pharma, Pfizer (Protalix), ISU ABXIS
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
235
Number of Tables & Figures
165
Customization Available
Yes, the report can be customized as per your need.
Global Gaucher Disease Market Report Segments:
The global Gaucher Disease market is segmented on the basis of:
Types
Enzyme Replacement Therapy, Substrate Reduction Therapy,
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Non-neuronopathic Gaucher Disease, Neuronopathic Gaucher Disease,
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sanofi
- Takeda
- Actelion Pharma
- Pfizer (Protalix)
- ISU ABXIS
Highlights of The Gaucher Disease Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Enzyme Replacement Therapy
- Substrate Reduction Therapy
- By Application:
- Non-neuronopathic Gaucher Disease
- Neuronopathic Gaucher Disease
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Gaucher Disease Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Gaucher disease is a rare genetic disorder that affects the body's ability to produce normal amounts of glucose, which can lead to serious health problems. Symptoms may include muscle weakness, seizures, and vision problems. Gaucher disease is most common in people of European descent but can also occur in other parts of the world. There is no known cure for Gaucher disease, but treatment options include medication and supportive care.
Some of the key players operating in the gaucher disease market are Sanofi, Takeda, Actelion Pharma, Pfizer (Protalix), ISU ABXIS.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Gaucher Disease Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Gaucher Disease Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Gaucher Disease Market - Supply Chain
4.5. Global Gaucher Disease Market Forecast
4.5.1. Gaucher Disease Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Gaucher Disease Market Size (000 Units) and Y-o-Y Growth
4.5.3. Gaucher Disease Market Absolute $ Opportunity
5. Global Gaucher Disease Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Gaucher Disease Market Size and Volume Forecast by Type
5.3.1. Enzyme Replacement Therapy
5.3.2. Substrate Reduction Therapy
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Gaucher Disease Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Gaucher Disease Market Size and Volume Forecast by Application
6.3.1. Non-neuronopathic Gaucher Disease
6.3.2. Neuronopathic Gaucher Disease
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Gaucher Disease Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Gaucher Disease Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Gaucher Disease Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Gaucher Disease Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Gaucher Disease Demand Share Forecast, 2019-2026
9. North America Gaucher Disease Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Gaucher Disease Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Gaucher Disease Market Size and Volume Forecast by Application
9.4.1. Non-neuronopathic Gaucher Disease
9.4.2. Neuronopathic Gaucher Disease
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Gaucher Disease Market Size and Volume Forecast by Type
9.7.1. Enzyme Replacement Therapy
9.7.2. Substrate Reduction Therapy
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Gaucher Disease Demand Share Forecast, 2019-2026
10. Latin America Gaucher Disease Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Gaucher Disease Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Gaucher Disease Market Size and Volume Forecast by Application
10.4.1. Non-neuronopathic Gaucher Disease
10.4.2. Neuronopathic Gaucher Disease
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Gaucher Disease Market Size and Volume Forecast by Type
10.7.1. Enzyme Replacement Therapy
10.7.2. Substrate Reduction Therapy
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Gaucher Disease Demand Share Forecast, 2019-2026
11. Europe Gaucher Disease Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Gaucher Disease Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Gaucher Disease Market Size and Volume Forecast by Application
11.4.1. Non-neuronopathic Gaucher Disease
11.4.2. Neuronopathic Gaucher Disease
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Gaucher Disease Market Size and Volume Forecast by Type
11.7.1. Enzyme Replacement Therapy
11.7.2. Substrate Reduction Therapy
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Gaucher Disease Demand Share, 2019-2026
12. Asia Pacific Gaucher Disease Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Gaucher Disease Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Gaucher Disease Market Size and Volume Forecast by Application
12.4.1. Non-neuronopathic Gaucher Disease
12.4.2. Neuronopathic Gaucher Disease
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Gaucher Disease Market Size and Volume Forecast by Type
12.7.1. Enzyme Replacement Therapy
12.7.2. Substrate Reduction Therapy
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Gaucher Disease Demand Share, 2019-2026
13. Middle East & Africa Gaucher Disease Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Gaucher Disease Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Gaucher Disease Market Size and Volume Forecast by Application
13.4.1. Non-neuronopathic Gaucher Disease
13.4.2. Neuronopathic Gaucher Disease
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Gaucher Disease Market Size and Volume Forecast by Type
13.7.1. Enzyme Replacement Therapy
13.7.2. Substrate Reduction Therapy
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Gaucher Disease Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Gaucher Disease Market: Market Share Analysis
14.2. Gaucher Disease Distributors and Customers
14.3. Gaucher Disease Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Sanofi
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Takeda
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Actelion Pharma
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Pfizer (Protalix)
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. ISU ABXIS
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
